What is Ernexa?
Ernexa Therapeutics is a preclinical-stage biotechnology firm headquartered in Cambridge, Massachusetts, dedicated to pioneering mRNA cell engineering technologies. The company's core mission is to develop novel therapies for cellular dysfunction, targeting a spectrum of indications including oncology, autoimmune disorders, and rare diseases. Ernexa has strategically in-licensed over 100 patents from Factor Bioscience, covering critical mRNA cell engineering technologies such as cell reprogramming, gene editing, and advanced delivery systems. Its lead candidate, ERNA-101, employs engineered induced mesenchymal stem cells (iMSCs) designed to leverage the natural tumor-homing capabilities of MSCs for targeted delivery of pro-inflammatory agents to the tumor microenvironment, with an initial focus on platinum-resistant ovarian cancer. Additionally, ERNA-102 is an iMSC therapy aimed at treating inflammatory and autoimmune conditions like rheumatoid arthritis by secreting anti-inflammatory cytokines. The company is actively pursuing strategic collaborations and partnerships for co-development and out-licensing of its therapeutic assets, including existing collaborations with entities like Lineage Cell Therapeutics for cell transplant therapies in neurological disorders.
How much funding has Ernexa raised?
Ernexa has raised a total of $168.7M across 9 funding rounds:
Debt
$15.1M
Private Equity
$40.6M
Multiple Rounds
$41.6M
Debt
$150K
Unspecified
$20M
Stock Offering
$40.7M
Stock/Share Issuance
$10.5M
Debt (2014): $15.1M, investors not publicly disclosed
Private Equity (2014): $40.6M, investors not publicly disclosed
Debt (2016): $2M, investors not publicly disclosed
Debt (2016): $6.4M, investors not publicly disclosed
Private Equity (2016): $33.2M, investors not publicly disclosed
Debt (2020): $150K with participation from PPP
Unspecified (2021): $20M, investors not publicly disclosed
Stock Issuance/Offering (2021): $40.7M, investors not publicly disclosed
Stock/Share Issuance (2026): $10.5M, investors not publicly disclosed
Key Investors in Ernexa
PPP
Public-Private Partnership
What's next for Ernexa?
With a substantial enterprise-level funding context and a recent major strategic investment, Ernexa Therapeutics is poised for significant advancement in its therapeutic pipeline. The company's focus on proprietary mRNA cell engineering technologies and its robust patent portfolio position it for continued innovation in oncology, autoimmune diseases, and rare genetic disorders. Future strategic moves are likely to involve further development of its lead candidates, ERNA-101 and ERNA-102, and the expansion of its collaborative network to accelerate clinical translation and market entry. The company's commitment to addressing high unmet medical needs suggests a trajectory towards becoming a key player in the advanced cell and nucleic acid therapy space.
See full Ernexa company page
